305 related items for PubMed ID: 16945177
21. Protective effect of rutin on lipids, lipoproteins, lipid metabolizing enzymes and glycoproteins in streptozotocin-induced diabetic rats.
Stanely Mainzen Prince P, Kannan NK.
J Pharm Pharmacol; 2006 Oct; 58(10):1373-83. PubMed ID: 17034661
[Abstract] [Full Text] [Related]
22. Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy.
Nakamura Y, Takeuchi H, Okuyama K, Akashi T, Jojima Y, Konno O, Akashi I, Hama K, Iwahori T, Ashizawa T, Hirano T, Oka K, Matsuno N, Nagao T.
Transplant Proc; 2005 May; 37(4):1725-7. PubMed ID: 15919445
[Abstract] [Full Text] [Related]
23. Relation of cyclosporine blood levels to adverse effects on lipoproteins.
Kuster GM, Drexel H, Bleisch JA, Rentsch K, Pei P, Binswanger U, Amann FW.
Transplantation; 1994 May 27; 57(10):1479-83. PubMed ID: 8197611
[Abstract] [Full Text] [Related]
24.
; . PubMed ID:
[No Abstract] [Full Text] [Related]
25. Pharmacokinetic and pharmacodynamic correlations of cyclosporine therapy in stable renal transplant patients: evaluation of long-term target C(2).
Brunet M, Campistol JM, Millán O, Vidal E, Esforzado N, Rojo I, Jiménez O, Oppenheimer F, Corbella J, Martorell J.
Int Immunopharmacol; 2003 Jul 27; 3(7):987-99. PubMed ID: 12810356
[Abstract] [Full Text] [Related]
26. Correlation Between C2 and AUC(0-4) in Renal Transplant Patients Treated With Diltiazem.
Aros CA, Schneider HO, Flores CA, Ardiles LG, Alruiz PA, Jerez V, Mezzano SA.
Transplant Proc; 2005 Apr 27; 37(3):1580-2. PubMed ID: 15866679
[Abstract] [Full Text] [Related]
27. Pharmacokinetics of enteric-coated mycophenolate sodium: comparative study in patients with autoimmune disease and renal allograft.
Neumann I, Fuhrmann H, Kanzler M, Fang IF, Jaeger A, Graf H, Bayer P, Kovarik J.
Expert Opin Pharmacother; 2008 Apr 27; 9(6):879-86. PubMed ID: 18377332
[Abstract] [Full Text] [Related]
28. Lipid profile in post renal transplant patients treated with cyclosporine in Sudan.
Suleiman B, El Imam M, Elsabigh M, Eltahir K, Eltahir A, Miskeen E.
Saudi J Kidney Dis Transpl; 2009 Mar 27; 20(2):312-7. PubMed ID: 19237829
[Abstract] [Full Text] [Related]
29. Combined cyclosporine and prednisolone therapy using cyclosporine blood concentration monitoring for adult patients with new-onset minimal change nephrotic syndrome: a single-center pilot randomized trial.
Shirai S, Imai N, Sueki S, Matsui K, Tominaga N, Sakurada T, Yasuda T, Kimura K, Shibagaki Y.
Clin Exp Nephrol; 2018 Apr 27; 22(2):283-290. PubMed ID: 28699032
[Abstract] [Full Text] [Related]
30. Pharmacokinetics of mycophenolic acid during the early period after renal transplant.
Nazemian F, Mohammadpur AH, Abtahi B, Naghibi M.
Exp Clin Transplant; 2007 Dec 27; 5(2):658-63. PubMed ID: 18194117
[Abstract] [Full Text] [Related]
31. Implication of cholesterol in cyclosporine pharmacodynamics in minimal change nephrotic syndrome.
Hirano T, Kawamura T, Fukuda S, Kohsaka S, Yoshikawa N, Yoshida M, Oka K.
Clin Pharmacol Ther; 2003 Dec 27; 74(6):581-90. PubMed ID: 14663460
[Abstract] [Full Text] [Related]
32. Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects.
Bergman AJ, Burke J, Larson P, Johnson-Levonas AO, Reyderman L, Statkevich P, Kosoglou T, Greenberg HE, Kraft WK, Frick G, Murphy G, Gottesdiener K, Paolini JF.
J Clin Pharmacol; 2006 Mar 27; 46(3):321-7. PubMed ID: 16490808
[Abstract] [Full Text] [Related]
33. Therapeutic drug monitoring of cyclosporine-lipoprotein levels.
Yau JC, Brunner LJ, Lopez-Berestein G, LeMaistre CF, Luke DR.
Pharmacotherapy; 1991 Mar 27; 11(4):291-5. PubMed ID: 1923909
[Abstract] [Full Text] [Related]
34. The effect of increased lipoprotein levels on the pharmacokinetics of cyclosporine A in the laboratory rat.
Brocks DR, Ala S, Aliabadi HM.
Biopharm Drug Dispos; 2006 Jan 27; 27(1):7-16. PubMed ID: 16278928
[Abstract] [Full Text] [Related]
35. A preliminary pharmacokinetic study of cyclosporine A in 10 Japanese renal transplant patients.
Takada K, Yoshikawa H, Muranishi S, Nagano S, Fukunishi T.
Int J Clin Pharmacol Ther Toxicol; 1987 Aug 27; 25(8):438-42. PubMed ID: 3308718
[Abstract] [Full Text] [Related]
36. The effect of cyclosporin A on the level of big endothelin in patients one year after orthotopic heart transplantation.
Kocík M, Málek I, Glagolicová A, Pirk J.
Transpl Int; 2004 Feb 27; 17(2):65-70. PubMed ID: 14634722
[Abstract] [Full Text] [Related]
37. Small dense low-density lipoprotein in renal transplant recipients: a potential target for prevention of cardiovascular complications?
Badiou S, Garrigue V, Dupuy AM, Chong G, Cristol JP, Mourad G.
Transplant Proc; 2006 Sep 27; 38(7):2314-6. PubMed ID: 16980076
[Abstract] [Full Text] [Related]
38. Optimal cyclosporine therapy--an Indian experience.
Raj DS, Somiah S, Mani K.
J Assoc Physicians India; 1996 Jan 27; 44(1):34-6. PubMed ID: 8773092
[Abstract] [Full Text] [Related]
39. Abbreviated AUC monitoring of cyclosporine more adequately identified patients at risk for acute rejection during induction of immunosuppressive therapy after kidney transplantation than recommended C2 concentration values.
Troncoso P, Ortiz AM, Jara A, Vilches S.
Transplant Proc; 2009 Jan 27; 41(1):127-30. PubMed ID: 19249495
[Abstract] [Full Text] [Related]
40. Correlation of C0 and C2 levels with lipid profiles in adolescent renal transplant recipients in the early and late posttransplant periods.
Soylu A, Kavukçu S, Türkmen MA, Kasap B, Soylu A, Bora S, Gülay H.
Transplant Proc; 2006 Jun 27; 38(5):1286-9. PubMed ID: 16797283
[Abstract] [Full Text] [Related]
Page: [Previous] [Next] [New Search]
